Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

14.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Epigenetic Regulation01:37

Epigenetic Regulation

3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma.

International journal of translational medicine (Basel, Switzerland)·2026
Same author

Neutrophil Gelatinase-Associated Lipocalin and Neutrophil-to-Lymphocyte Ratio as Indicators of Nephropathy in Type 2 Diabetic Mellitus Patients in Ghana: A Case-Control Study.

Health science reports·2026
Same author

Circular DNA has a ticket to ride chromosomes.

Nature·2025
Same author

Selective Depletion of Cancer Cells with Extrachromosomal DNA via Lentiviral Infection.

Cancer research communications·2025
Same author

Gestational Age-Specific Prevalence of Preeclampsia Among Pregnant Women in Ghana: A Hospital-Based Retrospective Observational Study.

BioMed research international·2025
Same author

Selective depletion of cancer cells with extrachromosomal DNA via lentiviral infection.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jan 16, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

Extrachromosomal DNA: A Trusted Path to Tumor Heterogeneity.

Emmanuel E Korsah1, Noah A Dusseau1, Eunhee Yi2

  • 1Department of Physiology, College of Natural Science, Michigan State University, East Lansing, Michigan.

Cancer Discovery
|October 6, 2025
PubMed
Summary

Extrachromosomal DNA (ecDNA) drives tumor heterogeneity and evolution. These studies reveal ecDNA

More Related Videos

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

10.8K
Genome-wide Purification of Extrachromosomal Circular DNA from Eukaryotic Cells
14:26

Genome-wide Purification of Extrachromosomal Circular DNA from Eukaryotic Cells

Published on: April 4, 2016

25.9K

Related Experiment Videos

Last Updated: Jan 16, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

10.8K
Genome-wide Purification of Extrachromosomal Circular DNA from Eukaryotic Cells
14:26

Genome-wide Purification of Extrachromosomal Circular DNA from Eukaryotic Cells

Published on: April 4, 2016

25.9K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Extrachromosomal DNA (ecDNA) is implicated in tumor heterogeneity.
  • Unequal segregation and ecDNA hub formation contribute to genomic and transcriptional variability.
  • The role of ecDNA in phenotypic and spatiotemporal heterogeneity requires further elucidation.

Purpose of the Study:

  • To investigate the role of ecDNA in enhancing tumor heterogeneity.
  • To understand how ecDNA confers a selective advantage during tumor evolution.
  • To expand the understanding of ecDNA's impact on phenotypic and spatiotemporal tumor characteristics.

Main Methods:

  • Analysis of ecDNA dynamics in tumor models.
  • Genomic and transcriptional profiling of tumors with ecDNA.
  • Assessment of phenotypic and spatiotemporal heterogeneity related to ecDNA.

Main Results:

  • Two studies presented in Cancer Discovery highlight ecDNA's role.
  • ecDNA enhances tumor heterogeneity at phenotypic and spatiotemporal levels.
  • ecDNA provides a significant selective advantage during tumor evolution.

Conclusions:

  • Extrachromosomal DNA is a critical driver of tumor heterogeneity.
  • Understanding ecDNA's mechanisms is crucial for cancer therapy.
  • Further research on ecDNA will advance cancer evolution insights.